Self-Calibrating Biosensor Array for Rapid Point-of-care Diagnosis

Information

  • Research Project
  • 7108429
  • ApplicationId
    7108429
  • Core Project Number
    R43RR022211
  • Full Project Number
    1R43RR022211-01A1
  • Serial Number
    22211
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/15/2006 - 18 years ago
  • Project End Date
    5/14/2008 - 16 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    8/15/2006 - 18 years ago
  • Budget End Date
    5/14/2008 - 16 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/7/2006 - 18 years ago
Organizations

Self-Calibrating Biosensor Array for Rapid Point-of-care Diagnosis

[unreadable] DESCRIPTION (provided by applicant): While routine point-of-care blood chemistry measurements can now be performed in clinical settings, quantitative high-sensitivity immunoassay measurements cannot. Thus, low-level serum markers for a variety of life-threatening conditions, such as sepsis, cannot be performed at the point of care. IA Inc.'s immunosensors possess the requisite speed and sensitivity needed to bring immunoassay to the point-of- care (POC), but lack the internal calibration and multiplexing features needed for measuring a panel of markers with the inter-sensor reproducibility required for clinical assays. The goal of this project is to extend IA, Inc's biosensor technology from the research environment into clinical settings by developing a self-calibrating, multi-analyte biosensor system which rapidly and accurately measures panels of low concentration disease markers in serum. The technology platform will be adaptable for rapid measurement of any blood analyte that currently requires more time-consuming immunoassay procedures. This project will focus on developing the two features that must be added to the existing technology platform in order to provide a point-of-care panel: self-calibration of sensors and multi-analyte capability. Phase II will provide a panel of inflammatory markers, such as cytokines, which are useful for diagnosis of life-threatening conditions such as sepsis and heart failure. By improving the speed with which clinical staff can make diagnosis, earlier treatment will reduce patient morbidity and mortality as well as the high cost incurred by more advanced disease progression. The Phase I Specific Aims include: 1) Develop inter-sensor calibration methods for data normalization; 2) Develop an instrument to measure 4-6 fluorescent emissions; 3) Perform calibrated simultaneous assay of 2 analytes; 4) Evaluate a universal sensor surface for use in antibody-based assays. The use of quantum dots for achieving calibration and multiplexing will be explored. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL CENTER FOR RESEARCH RESOURCES
  • Activity
    R43
  • Administering IC
    RR
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    205669
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    389
  • Ed Inst. Type
  • Funding ICs
    NCRR:205669\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    IA, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    Dexter
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48130
  • Organization District
    UNITED STATES